<A> validated reversed phase HPLC-method for the determination of olmesartan medoxomil in combination with hydrochlorothiazide

Arunadevi S., Birajdar; S.N., Meyyanathan; B., Suresh.
SPJ-Saudi Pharmaceutical Journal. 2009; 17 (2): 189-194
en Inglés | IMEMR | ID: emr-92847

Documentos relacionados

  1. Pharmacokinetics and tolerability of olmesartan medoxomil plus hydrochlorothiazide combination in healthy Chinese subjects: drug-drug interaction, bioequivalence, and accumulation.
  2. Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide, and rosuvastatin in healthy adult subjects.
  3. Pharmacokinetic properties and bioequivalence of olmesartan medoxomil/hydrochlorothiazide in healthy Korean male subjects.
  4. Ratio spectra derivative and zero-crossing difference spectrophotometric determination of olmesartan medoxomil and hydrochlorothiazide in combined pharmaceutical dosage form.
  5. Development and Validation of a UPLC-DAD Method for the Simultaneous Quantification of Eight Antihypertensive Drugs in the Pharmaceutical Matrix.
  6. Simultaneous analysis of irbesartan and hydrochlorothiazide: an improved HPLC method with the aid of a chemometric protocol.
  7. Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide.
  8. Development of a multivariate model with desirability-based optimization for determination of atenolol and hydrochlorothiazide by eco-friendly HPLC method with fluorescence detection.
  9. Validation of population pharmacokinetic models: a comparison of internal and external validation approaches for hydrochlorothiazide.
  10. Application of 3<sup>2</sup> factorial design for loratadine-loaded nanosponge in topical gel formulation: comprehensive in-vitro and ex vivo evaluations.